VEGF antibody has prolonged the survival of patients with colon cancer when in combination with chemotherapy; however, clinical observations revealed the resistance to anti-angiogenic therapy in colorectal cancer was caused by various intrinsic or acquired mechanisms, including the immunosuppressive tumor microenvironment [42]. This evidence concerns the gene VEGFA and malignant colon neoplasm.